Startup profile · funding coverage
AxoNeural Therapeutics funding, valuation and investors
Cleveland Clinic spinout developing nanoparticle-delivered therapeutics for neurodegenerative injury.
Keep track of AxoNeural Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Cleveland, OH
Overview
AxoNeural Therapeutics was founded as a Cleveland Clinic spin-off to develop nanoparticle-delivered therapeutics for neurodegenerative injuries and diseases. Lead concept Neupron targets neuroprotection in acute spinal cord injury. Company materials and SBIR listings associate Cleveland addresses including Cedar Avenue / Clinic campus.
Why AxoNeural Therapeutics is interesting
Clinic nanomedicine translation — Neupron antioxidant enzyme delivery for acute spinal cord injury; Cleveland HQ.
Key facts
- Cleveland Clinic spin-off (founded ~2020)
- Lead: Neupron nanoparticle antioxidant therapy
- Focus: spinal cord injury / neurodegenerative injury
- HQ Cleveland, OH
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about AxoNeural Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.